Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera
Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera
Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL
COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state
Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma
MRD validated as a surrogate endpoint for survival in AML
Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL
Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome
Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas
IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis
Exploring genomic insights in acute lymphoblastic leukaemia treatment
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types
Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma